Connect Biopharma Holdings (CNTB)

• Market cap: $142M
• 1 day: 7.23%
• 5 days: 7.69%
• 1 month: 2.86%
• 3 months: 0%
• 6 months: -10.95%
• Year to date: 0%
• 1 year: 235.46%
• 5 years: -83.2%
• 10 years: -86.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Employees: 64